Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

@article{Martinez2012ChangesIC,
  title={Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.},
  author={Esteban Martinez and Polyana M d'Albuquerque and Josep Mar{\'i}a Llibre and F{\'e}lix Guti{\'e}rrez and Daniel Podzamczer and Antonio Antela and Juan Berenguer and Pere Domingo and Xabier Moreno and Ignacio Mosquera P{\'e}rez and Judit Pich and Jose M. Gatell},
  journal={AIDS},
  year={2012},
  volume={26 18},
  pages={2315-26}
}
BACKGROUND : Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this strategy affects plasma biomarkers associated with atherosclerosis is unknown. METHODS : We assessed 48-week changes in fasting lipids and several biomarkers including serum high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein 1 (MCP-1), osteoprotegerin, interleukin (IL) 6, IL-10, tumor necrosis factor alpha… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Impaired lipid profile and insulin resistance in a cohort of Austrian HIV patients.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy • 2016
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…